One group of tumor-specific biomarkers called preferentially expressed antigen of melanoma (PRAME), also known as MAPE (melanoma antigen preferentially expressed in tumors), cancer-testis antigen 130 (CT130), and OIP4 (OPA-interacting protein 4) was initially identified in an autologous cytolytic T lymphocyte clone in a melanoma cell line [2]. Here, PRAME is linked to neoplasm.